Amgen's tezepelumab hits Phase 3 targets in esophageal disorder trial

Go back to Amgen's tezepelumab hits Phase 3 targets in esophageal disorder trial

TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS

October 20, 2026 9:01 AM EDT

Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52

Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at Week 52

THOUSAND OAKS,... More